BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
6/8 — Strong
Priority Review
LEQEMBI (lecanemab) by Eisai is amyloid beta-directed antibody interactions [moa]. Approved for amyloid beta-directed antibody [epc]. First approved in 2023.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQEMBI (lecanemab) is a monoclonal antibody directed against amyloid beta that treats early symptomatic Alzheimer's disease by slowing cognitive decline. It works by targeting and facilitating clearance of amyloid beta from the brain, addressing a key pathological hallmark of Alzheimer's disease. This represents the first anti-amyloid therapy to demonstrate meaningful clinical benefit in early cognitive decline.
$0.017BPart D
PeakGrowing
Product is at peak lifecycle stage with early adoption in Medicare Part D; commercial teams are scaling infrastructure for growing patient identification and access programs.
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Started Dec 2025
60 enrolled
Alzheimers Disease
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Started Feb 2025
3,000 enrolled
Alzheimer's Disease
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Started Sep 2024
105 enrolled
Alzheimer's Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Started Apr 2024
200 enrolled
Mild Cognitive ImpairmentAlzheimer Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Started Feb 2024
5,000 enrolled
Alzheimer's Disease
Worked on LEQEMBI at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.